Sanofi’s Q2 profits were lower than expected due to increased spending on developing new treatments, despite Dupixent’s sales of €3.8bn, up 21.1% from last year. The drug’s success expanded into the COPD market, boosting Sanofi’s total net sales to €9.9bn, up 10% at CER. Sanofi projects high single-digit annual sales growth and a rebound in EPS. The company aims to complete a €5bn share buyback in 2025. Despite recent acquisitions, Sanofi’s shares fell 1% on the Paris exchange. Dupixent is forecasted to drive Sanofi’s growth, with GlobalData estimating sales of €23.8bn by 2031.

Read more at Yahoo Finance: Dupixent sales spur Sanofi growth, but profits fall short